Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Nagle

Internal Medicine Washington, VA Medical Doctor

NPI 1356528111 CMS profile 687149

12625 Lee Hwy, Washington, VA 22747

Open in the dashboard

General payments

$7,583

396 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Nagle of Washington, VA is reported in the CMS Open Payments database as having received $7,583 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $905 44
2023 General $1,142 72
2022 General $1,541 96
2021 General $2,386 81
2020 General $775 51
2019 General $815 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Nagle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Nagle were reported at $19. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Nagle Internal Medicine median Middle half National median
2019 $815 $159 $48–$570 $163
2020 $775 $119 $33–$402 $114
2021 $2,386 $135 $37–$521 $132
2022 $1,541 $141 $42–$496 $149
2023 $1,142 $149 $45–$519 $160
2024 $905 $154 $47–$537 $164
2025 $19 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,381 101 payments
  2. Biohaven Pharmaceuticals, Inc. $1,279 5 payments
  3. Lilly USA, LLC $776 53 payments
  4. AbbVie, Inc. $675 40 payments
  5. AstraZeneca Pharmaceuticals LP $515 30 payments
  6. Amgen Inc. $442 22 payments
  7. Pfizer Inc. $281 18 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $268 14 payments
  9. GlaxoSmithKline, LLC. $165 11 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $152 14 payments
  11. Other $1,650 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,256 393 payments
  2. Consulting Fee $1,200 1 payment
  3. Debt forgiveness $121 1 payment
  4. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT $1,431 19 payments
  2. Ozempic $1,085 79 payments
  3. RYBELSUS $717 58 payments
  4. UBRELVY $413 22 payments
  5. FARXIGA $377 24 payments
  6. MOUNJARO $366 24 payments
  7. JARDIANCE $281 19 payments
  8. AIMOVIG $269 12 payments
  9. TRULICITY $232 17 payments
  10. Repatha $219 12 payments
  11. Other $4,228 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

2,286

Median for Internal Medicine: 777

Drug cost

$204,524

Median for Internal Medicine: $73,373

Branded share of claims

16.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 58 $108,607
Eliquis Apixaban Brand 35 $26,555
Januvia Sitagliptin Phosphate Brand 15 $21,663
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $12,245
Tresiba Flextouch U-100 Insulin Degludec Brand 15 $8,215
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 23 $4,091
Wixela Inhub Fluticasone Propion/Salmeterol Brand 13 $2,016
Rosuvastatin Calcium Generic 96 $1,804
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 15 $1,793
Esomeprazole Magnesium Generic 14 $1,362

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$53,153

Of which drugs: $999

Medicare patients

282

Average age 75

Services billed

943

115 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 34%
Diabetes 27%
Ischemic heart disease 21%
Atrial fibrillation 18%
Heart failure 14%
Chronic kidney disease 14%
Depression 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $126
$126 — —
Auvelity
  • Axsome Therapeutics, Inc. $98
$98 — —
ZEPBOUND
  • Lilly USA, LLC $80
$80 — —
RYBELSUS
  • Novo Nordisk Inc $64
$64 — —
Ozempic
  • Novo Nordisk Inc $64
$64 58 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record